InvestSMART

Proteomics International Laboratories Ltd (ASX:PIQ)

ALERT: Price-sensitive ASX Announcement for PIQ
Current share price for PIQ : $0.175 -0.395 (-69.30%)+
Announcement
Release
30 Jan 2026 8:25AM
Price at Release
$0.570
Full Release
download
Summary
Proteomics International Laboratories Ltd's quarterly report ending 31 December 2025 reveals cash receipts from customers of $127,000 and significant government grants of $2,687,000. Operating cash outflows were primarily driven by research and development expenses amounting to $965,000. The company maintained a net cash outflow from operations of $182,000 for the quarter, with investing activities leading to an additional outflow of $1,986,000. Financing activities resulted in a minor outflow of $182,000. Consequently, cash reserves decreased from $10,019,000 to $7,669,000 over the quarter. Payments to related parties totaled $194,000, mainly for director remuneration. The firm reports an estimated 42 quarters of funding available at the current cash flow rate, with no existing loan facilities or credit standby arrangements.
Key Points
  • Proteomics International Laboratories Ltd reported cash receipts from customers totaling $127,000 for the current quarter and $1,991,000 year-to-date.
  • Research and development payments were $965,000 for the current quarter and $1,996,000 year-to-date.
  • The company received government grants and tax incentives amounting to $2,687,000.
  • There was a net cash outflow from operating activities of $182,000 for the quarter, and $951,000 year-to-date.
  • Investing activities resulted in a net cash outflow of $1,986,000 for the current quarter and $2,059,000 year-to-date.
  • Financing activities yielded a net cash outflow of $182,000 for the quarter and $358,000 year-to-date.
  • Cash and cash equivalents decreased from $10,019,000 at the beginning of the quarter to $7,669,000 by the end.
  • Payments to related parties during the quarter totaled $194,000, which relate to remuneration for Directors.
  • The company has no loan facilities or credit standby arrangements available.
  • Proteomics International Laboratories Ltd estimates 42 quarters of funding available with the current cash flow.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.